Drugs Containing Excipient (Inactive Ingredient) TERT-BUTYL ALCOHOL

Generic drugs containing TERT-BUTYL ALCOHOL excipient

Company	Ingredient	NDC	Excipient
Rhodes Pharmaceuticals LP	dextroamphetamine saccharate, amphetamine aspartate monohydrate, dextroamphetamine sulfate, and amphetamine sulfate	42858-055	TERT-BUTYL ALCOHOL
Medimetriks Pharmaceuticals Inc	ketoconazole	43538-530	TERT-BUTYL ALCOHOL
Padagis Israel Pharmaceuticals Ltd	ketoconazole	45802-532	TERT-BUTYL ALCOHOL
A-S Medication Solutions	cefaclor	50090-1602	TERT-BUTYL ALCOHOL
Carlsbad Technology Inc	cefaclor	61442-171	TERT-BUTYL ALCOHOL
Bryant Ranch Prepack	cefaclor	63629-1007	TERT-BUTYL ALCOHOL

Tert-Butyl Alcohol Excipient Market Dynamics and Financial Trajectory

Last updated: August 18, 2026

Tert-butyl alcohol, also called 2-methyl-2-propanol or TBA, is a niche pharmaceutical solvent and lyophilization aid rather than a major standalone excipient. Its commercial value comes from enabling drug formulation and freeze-drying processes, not from high-volume finished-dose consumption. Demand should track injectable biologics, poorly water-soluble drugs, and lyophilized products, while pricing remains linked to petrochemical feedstocks and industrial solvent supply.

Public companies do not report tert-butyl alcohol revenue separately. The market therefore cannot be valued reliably as an independent pharmaceutical-excipient category from public filings. The strongest investment indicators are pharmaceutical-grade supply qualification, customer adoption in sterile manufacturing, regulatory documentation, and exposure to isobutylene-based production economics.

What is tert-butyl alcohol used for in pharmaceutical manufacturing?

Tert-butyl alcohol is used primarily as a solvent, cosolvent, processing aid, and lyophilization formulation component.

Attribute	Data
Chemical name	2-methyl-2-propanol
Common name	tert-butyl alcohol, tertiary butanol, TBA
CAS number	75-65-0
Molecular formula	C4H10O
Molecular weight	74.12 g/mol
Physical form	Low-melting solid or liquid near ambient temperature
Primary pharmaceutical role	Solvent, cosolvent, freeze-drying aid, process solvent
Main dosage-form exposure	Parenteral and lyophilized products
Commercial category	Specialty solvent and process excipient

Tert-butyl alcohol is attractive in lyophilization because it is water-miscible, can improve the solubility of hydrophobic compounds, and can alter freezing and drying behavior. Its use may support more uniform cake structure and improve the processing of compounds that are difficult to formulate in water alone.

The molecule’s low melting point, approximately 25.5°C, creates a manufacturing consideration. Storage, transfer, and process controls must prevent unwanted solidification or inconsistent handling. The same property can affect freeze-drying cycle design and equipment operation.

Tert-butyl alcohol is not generally the principal bulking agent in a finished lyophilized dosage form. Conventional bulking agents such as mannitol, sucrose, trehalose, and lactose may remain in the formulation after drying. Tert-butyl alcohol is more commonly evaluated as a volatile formulation or process component that is removed, reduced, or controlled during lyophilization.

How large is the pharmaceutical tert-butyl alcohol market?

The pharmaceutical segment is small relative to industrial and chemical uses, and public market reports rarely isolate it.

Tert-butyl alcohol is used across chemical manufacturing, solvents, coatings, fuels, and laboratory applications. Pharmaceutical demand is a specialized subset driven by formulation development and manufacturing requirements. It does not have the volume profile of high-use excipients such as polyethylene glycol, propylene glycol, ethanol, polysorbates, or mannitol.

A practical market model is:

Market driver	Effect on tert-butyl alcohol demand
Growth in lyophilized injectables	Positive
Expansion of biologics manufacturing	Positive
Adoption of solvent-assisted freeze-drying	Positive
Generic oral-solid-dose production	Limited
Industrial solvent capacity	Determines availability
Isobutylene and MTBE economics	Influences cost
Sterile-grade qualification	Supports pricing premium
Replacement by ethanol, acetonitrile, or other solvents	Negative in selected applications
Residual-solvent controls	Limits use level

Revenue exposure is likely concentrated among chemical producers and specialty distributors rather than excipient companies that report TBA as a material product line. A pharmaceutical-grade producer may earn a premium for documentation, batch consistency, low impurity levels, validated packaging, and supply continuity. The premium is commercially important even when the underlying chemical is commoditized.

What is driving the financial trajectory for tert-butyl alcohol?

The financial trajectory is likely to be stable to moderately positive in pharmaceutical applications, with cyclical pricing at the raw-material level.

Pharmaceutical demand

The most favorable demand segment is sterile manufacturing, especially lyophilized biologics, peptides, vaccines, enzymes, and injectable small molecules. The number of approved and pipeline products requiring cold-chain logistics or freeze-drying supports long-term demand for formulation solvents and process aids.

Demand is less correlated with tablet and capsule volumes. Tert-butyl alcohol has no broad role as a traditional tablet binder, filler, disintegrant, or coating polymer.

Feedstock exposure

Commercial production is associated with tert-butanol chemistry based on isobutylene and related petrochemical streams. Supply economics can be influenced by:

• crude oil and natural gas prices;
• refinery operating rates;
• isobutylene availability;
• MTBE and fuel-blending demand;
• chemical plant outages;
• transportation and hazardous-material costs;
• regional capacity utilization.

This creates a split financial profile. Pharmaceutical consumption may grow steadily, but supplier margins can move sharply when petrochemical feedstocks tighten or when industrial demand changes.

Quality premium

Pharmaceutical buyers do not purchase only molecular identity. They also require documented impurity control, reproducible water content, controlled nonvolatile residue, appropriate packaging, traceability, and change-control commitments.

A supplier with a qualified pharmaceutical-grade product can protect margins better than a supplier competing only on bulk chemical price. The commercial value of a qualified supplier relationship rises after the solvent is incorporated into a validated manufacturing process because replacement requires comparability work, supplier qualification, and sometimes regulatory assessment.

Substitution risk

Tert-butyl alcohol can be replaced in some applications by ethanol, isopropanol, acetone, acetonitrile, or other solvent systems. The substitution decision depends on:

• drug solubility;
• freezing behavior;
• toxicity and residual-solvent limits;
• lyophilization cycle time;
• cake morphology;
• equipment compatibility;
• process yield;
• regulatory history.

Substitution is therefore formulation-specific. A lower-cost solvent is not automatically a viable replacement if it changes product quality or requires redevelopment of a validated cycle.

What regulatory status applies to tert-butyl alcohol as an excipient?

Tert-butyl alcohol is regulated according to its function, route, concentration, residual level, and manufacturing context. It should not be treated as automatically cleared for unrestricted use in every pharmaceutical dosage form.

ICH Q3C classifies residual solvents according to toxicological risk and establishes permitted daily exposure and concentration concepts for solvents used in drug manufacturing. Where tert-butyl alcohol is used as a process solvent, the manufacturer must establish appropriate controls and demonstrate that residual levels are acceptable under the applicable regulatory framework [1].

The FDA inactive ingredient database is the principal public reference for excipients that have appeared in approved drug products. An entry, where applicable, is route- and dosage-form-specific. It does not create a universal approval for every formulation or concentration [2].

Relevant regulatory controls include:

• identity and strength testing of incoming materials;
• impurity and water-content specifications;
• control of residual solvent in the drug substance or drug product;
• validated removal or reduction during drying;
• stability assessment;
• supplier qualification;
• change-control documentation;
• compliance with current good manufacturing practice.

For parenteral products, the regulatory burden is higher because residual solvent, particulate matter, sterility, endotoxin, container closure, and extractables and leachables all affect product quality.

What patents protect pharmaceutical uses of tert-butyl alcohol?

No meaningful composition-of-matter exclusivity remains for tert-butyl alcohol. It is an established chemical with extensive prior art and no realistic new-molecule patent barrier.

Potential intellectual-property protection exists at the application level:

IP category	Potential protection
Lyophilization formulation	Defined solvent-water ratios, excipient combinations, or cycle conditions
Drug-specific formulation	Use with a particular active ingredient or biologic
Manufacturing process	Addition, freezing, drying, or solvent-removal sequence
Device or equipment	Controlled-temperature handling of low-melting TBA
Quality-control method	Detection or quantification of residual tert-butyl alcohol
Packaging	Containers and systems that control evaporation or solidification

These rights generally protect a formulation or process, not the TBA molecule itself. A patent claim directed to a particular drug formulation may create commercial value if the product depends on that formulation. It does not necessarily prevent another manufacturer from selling or using tert-butyl alcohol in unrelated products.

Patent analysis should focus on drug-specific portfolios, formulation claims, and lyophilization-process claims. A generic TBA patent search alone will overstate the strength of the relevant estate.

When does tert-butyl alcohol lose exclusivity?

Tert-butyl alcohol has no meaningful pharmaceutical exclusivity period comparable to an innovative drug.

Exclusivity type	Status
New chemical entity exclusivity	Not applicable
Drug-specific regulatory exclusivity	Not applicable to the excipient itself
Composition-of-matter patent	Effectively expired for this established molecule
Orange Book listing	No standalone TBA listing is expected
Biosimilar exclusivity	Not applicable
Formulation patent	Depends on the protected drug product and patent term
Process patent	Depends on claim scope and expiration
Supplier qualification protection	Commercial rather than statutory

The relevant exclusivity may belong to a finished drug that uses tert-butyl alcohol in development or manufacturing. That protection comes from the drug’s patents, regulatory exclusivity, trade secrets, or validated process, not from the excipient.

Does tert-butyl alcohol create Paragraph IV or biosimilar risk?

Tert-butyl alcohol itself does not generate Paragraph IV litigation or biosimilar litigation.

Paragraph IV challenges address patents listed for an approved small-molecule drug in the FDA Orange Book. An excipient supplier is not the usual target of a Paragraph IV filing. A generic applicant could challenge a drug patent involving a TBA-containing formulation, but the legal dispute would concern the drug product and the asserted patent claims.

Biosimilar risk is also indirect. Biologic manufacturers may use tert-butyl alcohol during formulation development or lyophilization, but biosimilar litigation typically concerns biologic patents covering the molecule, formulation, manufacturing process, delivery device, or method of treatment. A TBA-related process claim could matter if it is essential to a biosimilar’s manufacturing route, but this is a product-specific issue.

What manufacturing and intellectual-property barriers affect supply?

The principal barriers are operational and regulatory rather than molecular.

Manufacturing barriers

Pharmaceutical buyers may require:

• validated impurity profiles;
• low and controlled water content;
• batch-to-batch consistency;
• suitable container closure;
• temperature-controlled handling;
• documented cleaning and cross-contamination controls;
• audit access;
• long-term supply agreements;
• regulatory support for manufacturing changes.

Because tert-butyl alcohol can solidify near room temperature, physical handling may be more demanding than for solvents that remain liquid across standard warehouse conditions.

Intellectual-property barriers

The main IP risks arise when TBA is integrated into a proprietary formulation or manufacturing sequence. Relevant patents may be held by:

• the drug innovator;
• a contract development and manufacturing organization;
• a specialty formulation company;
• a manufacturer of lyophilization equipment;
• a university or research institution.

These rights may limit the use of a specific TBA-based process without preventing procurement of the solvent itself.

How does tert-butyl alcohol compare with other pharmaceutical solvents?

Solvent	Relative pharmaceutical role	Key advantage	Main limitation
Tert-butyl alcohol	Specialized solvent and lyophilization aid	Water miscibility and utility for hydrophobic compounds	Low melting point and residual-solvent control
Ethanol	Broad solvent and cosolvent	Familiar regulatory profile and broad availability	May alter protein stability or drying behavior
Isopropanol	Process solvent and cleaning solvent	Low cost and established supply	Less suitable for some formulation systems
Acetone	Process solvent	High volatility and strong solvency	Formulation compatibility and residual control
Acetonitrile	Analytical and process solvent	Strong solvency	Higher toxicological and cost concerns
Propylene glycol	Cosolvent and plasticizer	Low volatility and formulation utility	Remains in product and can affect tolerability
Water for injection	Primary parenteral vehicle	Strong regulatory familiarity	Limited solubility for hydrophobic drugs

Tert-butyl alcohol is most defensible where it solves a specific formulation or drying problem. It is less competitive where a standard solvent already provides acceptable solubility, stability, and process performance.

What is the competitive landscape for pharmaceutical-grade tert-butyl alcohol?

Competition is likely fragmented across chemical producers, solvent refiners, and specialty distributors. The relevant competitive variables are:

1. Pharmaceutical-grade documentation.
2. Regional production and delivery capacity.
3. Impurity and water specifications.
4. Packaging suitable for regulated manufacturing.
5. Change-notification practices.
6. Audit and quality-support capabilities.
7. Price stability and supply continuity.

Large chemical producers may have feedstock and scale advantages. Specialty distributors may compete through regional inventory, smaller batch sizes, technical support, and regulatory documentation. Contract manufacturers can influence supplier selection because they often standardize excipients across multiple drug-development programs.

No single supplier should be assumed to control pharmaceutical TBA demand without product-level qualification data and customer evidence.

What are the generic launch and revenue risks?

The direct revenue risk to a TBA supplier is low when the solvent is used across many unrelated products. A supplier becomes more exposed when sales depend on one injectable, one sponsor, or one contract manufacturing network.

Generic launch can reduce demand for an innovator’s specific formulation, but it does not necessarily eliminate TBA demand. If a generic uses the same lyophilization process, demand may continue. If it redesigns the formulation or uses a different solvent, the supplier may lose that account.

The highest-risk events are:

• discontinuation of a lyophilized product;
• replacement of TBA during formulation optimization;
• failure to meet a customer’s pharmaceutical specification;
• plant shutdown or feedstock disruption;
• regulatory concern over residual solvent;
• customer consolidation into a competing qualified supplier.

Key Takeaways

• Tert-butyl alcohol is a niche pharmaceutical solvent and lyophilization aid, not a high-volume conventional excipient.
• Its strongest demand exposure is to lyophilized injectables, biologics, peptides, vaccines, and poorly water-soluble drugs.
• Public companies do not disclose standalone pharmaceutical TBA revenue, so independent market-size estimates require bottom-up supplier and customer data.
• Financial performance is shaped by pharmaceutical-grade qualification premiums and petrochemical feedstock volatility.
• Tert-butyl alcohol has no meaningful standalone drug exclusivity, Orange Book position, Paragraph IV exposure, or biosimilar exclusivity.
• The important IP is drug-specific formulation and manufacturing IP, not composition-of-matter protection for TBA.
• Supply-chain qualification, impurity control, temperature handling, and residual-solvent compliance are stronger commercial barriers than patents.

FAQs about tert-butyl alcohol in pharmaceuticals

Is tert-butyl alcohol the same as tertiary butanol?

Yes. Tert-butyl alcohol, tertiary butanol, and 2-methyl-2-propanol refer to the same chemical compound, CAS 75-65-0.

Is tert-butyl alcohol used in injectable drugs?

It can be used during formulation or lyophilization of injectable products, but acceptability depends on route, concentration, residual level, product formulation, and regulatory justification.

Is tert-butyl alcohol a Class 3 residual solvent?

Its regulatory treatment must be assessed under the applicable version of ICH Q3C and the product-specific control strategy. The manufacturer must establish and verify acceptable residual levels rather than rely on the solvent name alone [1].

Can ethanol replace tert-butyl alcohol in a lyophilized formulation?

Sometimes, but substitution requires formulation and process redevelopment. Solubility, protein stability, freezing behavior, cake structure, drying time, and residual-solvent performance may change.

Does tert-butyl alcohol have an FDA Orange Book patent?

No standalone Orange Book patent position should be expected for the excipient. Any relevant listed patent would relate to a specific approved drug product or formulation, not to general ownership of tert-butyl alcohol.

References

1. International Council for Harmonisation. (2021). ICH Q3C(R8): Impurities: Guideline for residual solvents. https://www.ich.org/page/quality-guidelines

2. U.S. Food and Drug Administration. (n.d.). Inactive ingredient database. https://www.accessdata.fda.gov/scripts/cder/iig/index.cfm

3. U.S. Food and Drug Administration. (2023). Orange Book: Approved drug products with therapeutic equivalence evaluations. https://www.accessdata.fda.gov/scripts/cder/ob/index.cfm

4. National Center for Biotechnology Information. (n.d.). PubChem compound summary for tert-butanol. PubChem. https://pubchem.ncbi.nlm.nih.gov/compound/Tert-Butyl-Alcohol

5. United States Pharmacopeial Convention. (2023). United States Pharmacopeia and National Formulary. USP Convention.